Table 2.
Patient characteristics after propensity score matching.
| Characteristic | All Patients | LEN Combined with TIT | LEN Monotherapy | p |
|---|---|---|---|---|
| n | 38 | 19 | 19 | |
| Age (years old) | 67 (44–79) | 68 (44–78) | 66 (44–79) | 0.578 |
| Sex (female/male) | 8/30 | 4/15 | 4/15 | n.s. |
| PS (0/1/2) | 33/5/0 | 17/2/0 | 16/3/0 | 0.305 |
| Etiology (HBV/HCV/Others) | 12/11/15 | 5/5/9 | 7/6/6 | 0.597 |
| ALBI score (Median (range)) |
−2.66 (−3.33–−1.91) |
−2.69 (−3.06–−1.91) |
−2.65 (−3.33–−2.10) |
0.883 |
| m-ALBI grade (1/2a/2b) | 22/8/8 | 11/3/5 | 11/5/3 | 0.603 |
| Tumor size (mm) | 38 (11–131) | 37 (11–131) | 40 (11–92) | 0.770 |
| Number tumors <5/≥5 |
9/29 | 5/14 | 4/15 | 0.702 |
| Macrovascular invasion (No/Yes) |
25/13 | 11/8 | 14/5 | 0.303 |
| Extrahepatic spread (No/Yes) |
12/26 | 7/12 | 5/14 | 0.484 |
| Initial dose of LEN | 0.338 | |||
| 12 mg | 12 | 5 | 7 | |
| 8 mg | 23 | 11 | 12 | |
| 8 mg weekend methods | 1 | 1 | 0 | |
| 4 mg | 1 | 1 | 0 | |
| 4 mg weekend methods | 1 | 1 | 0 | |
| Combination therapy | n.s. | |||
| TACE | 7 | 7 | ||
| HAIC | 12 | 12 | ||
| AFP (ng/mL) | 59.6 (1.6–56,225) |
78.9 (1.7–56,225) |
133.0 (1.0–146,260) |
0.605 |
| Treatment line (1st/2nd/3rd) |
31/4/3 | 15/3/1 | 16/1/2 | 0.492 |
Data are expressed as a median (range) or number. Abbreviations: LEN, lenvatinib; TIT; Transcatheter intra-arterial therapies; PS, Performance Status; HBV, hepatitis B virus; HCV, hepatitis C virus; ALBI score, albumin-bilirubin score; TACE, transcatheter arterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; AFP, α-fetoprotein.